Cue Biopharma is trading 5.17% lower at $26.03; no company-specific announcement or clear catalyst was identified for the September 29 decline.
- Positive CUE-221 Phase 2 results were announced September 20, but do not establish the cause of the current move.
- The broader market was only slightly lower; available evidence does not show macro sentiment explains the stock-specific drop.
- Price context also shows a sharp prior-session decline, with its cause unclear.